Trial Profile
A Phase 1, 2-Stage, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 Following Single and Multiple Ascending Doses in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs BBT 877 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; First in man
- Sponsors Bridge Biotherapeutics
- 15 Jan 2020 Status changed from recruiting to completed.
- 22 Oct 2019 Planned End Date changed from 31 Jul 2019 to 31 Dec 2019.
- 22 Oct 2019 Planned primary completion date changed from 31 Jul 2019 to 30 Nov 2019.